SAN CARLOS, Calif., Aug. 27 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present at the 2007 NewsMakers in the Biotech Industry Conference on Thursday, September 6, 2007. Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer, will be presenting.
Date: Thursday, September 6, 2007 Time: 2:00 p.m. ET Place: Millennium Broadway Hotel, New York, NY
An audio Web cast of the Company’s presentation will be available by going to the investor relations section of NeurogesX’ Web site at www.neurogesx.com. A replay of the presentation will be available for 15 days.
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy. NeurogesX’s late stage product portfolio is led by product candidate NGX-4010, a topical patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Two Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, one in PHN and one in HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the advantages of NGX-4010 over other pain therapies. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX’ product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX- 4010. For further information regarding these and other risks related to NeurogesX’ business, investors should consult NeurogesX’ filings with the Securities and Exchange Commission.
NeurogesX The Ruth Group Stephen Ghiglieri Investors / Media (650) 508-2116 Stephanie Carrington / Jason Rando sghiglieri@neurogesx.com (646) 536-7017 / 7025 scarrington@theruthgroup.comjrando@theruthgroup.com
NeurogesX, Inc.
CONTACT: Stephen Ghiglieri of NeurogesX, +1-650-508-2116,sghiglieri@neurogesx.com; or Investors, Stephanie Carrington,+1-646-536-7017, scarrington@theruthgroup.com, or Media, Jason Rando,+1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group, forNeurogesX, Inc.
